B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas

Cancer Cell

Volumn 25, Issue 6, 2014, Pages 809-821

  Affara, Nesrine I ^a   Ruffell, Brian ^a,c,d   Medler, Terry R ^c   Gunderson, Andrew J ^c   Johansson, Magnus ^a   Bornstein, Sophia ^d   Bergsland, Emily ^a,b   Steinhoff, Martin ^a   Li, Yijin ^e   Gong, Qian ^e   Ma, Yan ^e   Wiesen, Jane F ^a,c   Wong, Melissa H ^c,d   Kulesz Martin, Molly ^c,d   Irving, Bryan ^e   Coussens, Lisa M ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CD8 ANTIGEN; PACLITAXEL; PLATINUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; DOWNSTREAM PROCESSING; FEMALE; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; CHO CELLS; CRICETULUS; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MICE; MICE, TRANSGENIC; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PHENOTYPE; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902465821     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.04.026     Document Type: Article

References (53)

1. Albers A., Abe K., Hunt J., Wang J., Lopez-Albaitero A., Schaefer C., Gooding W., Whiteside T.L., Ferrone S., DeLeo A., Ferris R.L. Antitumor activity of human papillomavirus type 16 E7-specific Tcells against virally infected squamous cell carcinoma of the head and neck. Cancer Res. 2005, 65:11146-11155.
2. Ammirante M., Luo J.L., Grivennikov S., Nedospasov S., Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010, 464:302-305.
3. Andreu P., Johansson M., Affara N.I., Pucci F., Tan T., Junankar S., Korets L., Lam J., Tawfik D., DeNardo D.G., et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010, 17:121-134.
4. Arbeit J.M., Münger K., Howley P.M., Hanahan D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J.Virol. 1994, 68:4358-4368.
5. Arbeit J.M., Olson D.C., Hanahan D. Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice. Oncogene 1996, 13:1847-1857.
6. Bahjat F.R., Pine P.R., Reitsma A., Cassafer G., Baluom M., Grillo S., Chang B., Zhao F.F., Payan D.G., Grossbard E.B., Daikh D.I. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 2008, 58:1433-1444.
7. Barbera-Guillem E., Nelson M.B., Barr B., Nyhus J.K., May K.F., Feng L., Sampsel J.W. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol. Immunother. 2000, 48:541-549.
8. Braselmann S., Taylor V., Zhao H., Wang S., Sylvain C., Baluom M., Qu K., Herlaar E., Lau A., Young C., et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J.Pharmacol. Exp. Ther. 2006, 319:998-1008.
9. Chapoval A.I., Fuller J.A., Kremlev S.G., Kamdar S.J., Evans R. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and Tcell-mediated effects antagonized by B cells. J.Immunol. 1998, 161:6977-6984.
10. Chaturvedi A.K. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J.Adolesc. Health 2010, 46:S20-26.
11. Chaturvedi A.K., Engels E.A., Pfeiffer R.M., Hernandez B.Y., Xiao W., Kim E., Jiang B., Goodman M.T., Sibug-Saber M., Cozen W., et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J.Clin. Oncol. 2011, 29:4294-4301.
12. Colonna L., Catalano G., Chew C., D'Agati V., Thomas J.W., Wong F.S., Schmitz J., Masuda E.S., Reizis B., Tarakhovsky A., Clynes R. Therapeutic targeting of Syk in autoimmune diabetes. J.Immunol. 2010, 185:1532-1543.
13. Coussens L.M., Hanahan D., Arbeit J.M. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am. J. Pathol. 1996, 149:1899-1917.
14. Coussens L.M., Raymond W.W., Bergers G., Laig-Webster M., Behrendtsen O., Werb Z., Caughey G.H., Hanahan D. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 1999, 13:1382-1397.
15. Coussens L.M., Tinkle C.L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490.
16. Daniel D., Meyer-Morse N., Bergsland E.K., Dehne K., Coussens L.M., Hanahan D. Immune enhancement of skin carcinogenesis by CD4+ Tcells. J.Exp. Med. 2003, 197:1017-1028.
17. Daniel D., Chiu C., Giraudo E., Inoue M., Mizzen L.A., Chu N.R., Hanahan D. CD4+ Tcell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res. 2005, 65:2018-2025.
18. de Visser K.E., Korets L.V., Coussens L.M. Early neoplastic progression is complement independent. Neoplasia 2004, 6:768-776.
19. de Visser K.E., Korets L.V., Coussens L.M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005, 7:411-423.
20. DeNardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., Gallagher W.M., Wadhwani N., Keil S.D., Junaid S.A., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011, 1:54-67.
21. Ginos M.A., Page G.P., Michalowicz B.S., Patel K.J., Volker S.E., Pambuccian S.E., Ondrey F.G., Adams G.L., Gaffney P.M. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res. 2004, 64:55-63.
22. Gökbuget N., Hoelzer D. Novel antibody-based therapy for acute lymphoblastic leukaemia. Best Pract. Res. Clin. Haematol. 2006, 19:701-713.
23. González-Martín A., Gómez L., Lustgarten J., Mira E., Mañes S. Maximal Tcell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) Tcells. Cancer Res. 2011, 71:5455-5466.
24. Gunderson A.J., Coussens L.M. B cells and their mediators as targets for therapy in solid tumors. Exp. Cell Res. 2013, 319:1644-1649.
25. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N.Engl. J. Med. 2010, 363:711-723.
26. Hong M., Puaux A.L., Huang C., Loumagne L., Tow C., Mackay C., Kato M., Prévost-Blondel A., Avril M.F., Nardin A., Abastado J.P. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res. 2011, 71:6997-7009.
27. Horikawa M., Minard-Colin V., Matsushita T., Tedder T.F. Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J.Clin. Invest. 2011, 121:4268-4280.
28. Huang H., Benoist C., Mathis D. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc. Natl. Acad. Sci. USA 2010, 107:4658-4663.
29. Inoue S., Leitner W.W., Golding B., Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer Res. 2006, 66:7741-7747.
30. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N.Engl. J. Med. 2010, 363:411-422. IMPACT Study Investigators.
31. Kobayashi A., Darragh T., Herndier B., Anastos K., Minkoff H., Cohen M., Young M., Levine A., Grant L.A., Hyun W., et al. Lymphoid follicles are generated in high-grade cervical dysplasia and have differing characteristics depending on HIV status. Am. J. Pathol. 2002, 160:151-164.
32. Maurer M.A., Rakocevic G., Leung C.S., Quast I., Lukačišin M., Goebels N., Münz C., Wardemann H., Dalakas M., Lünemann J.D. Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. J.Clin. Invest. 2012, 122:1393-1402.
33. McLaughlin P., White C.A., Grillo-Lopez A.J., Maloney D.G. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology 1998, 12(Huntingt):1763-1769. discussion 1769-1770, 1775-1777.
34. Moseman E.A., Iannacone M., Bosurgi L., Tonti E., Chevrier N., Tumanov A., Fu Y.X., Hacohen N., von Andrian U.H. B cell maintenance of subcapsular sinus macrophages protects against a fatal viral infection independent of adaptive immunity. Immunity 2012, 36:415-426.
35. Nelson B.H. CD20+ B cells: the other tumor-infiltrating lymphocytes. J.Immunol. 2010, 185:4977-4982.
36. Ochoa-Callejero L., Pérez-Martínez L., Rubio-Mediavilla S., Oteo J.A., Martínez A., Blanco J.R. Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS ONE 2013, 8:e53992.
37. Olkhanud P.B., Damdinsuren B., Bodogai M., Gress R.E., Sen R., Wejksza K., Malchinkhuu E., Wersto R.P., Biragyn A. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4[U+207A] Tcells to T-regulatory cells. Cancer Res. 2011, 71:3505-3515.
38. Perricone M.A., Smith K.A., Claussen K.A., Plog M.S., Hempel D.M., Roberts B.L., St George J.A., Kaplan J.M. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J.Immunother. 2004, 27:273-281.
39. Qin Z., Richter G., Schüler T., Ibe S., Cao X., Blankenstein T. B cells inhibit induction of Tcell-dependent tumor immunity. Nat. Med. 1998, 4:627-630.
40. Rauch P.J., Chudnovskiy A., Robbins C.S., Weber G.F., Etzrodt M., Hilgendorf I., Tiglao E., Figueiredo J.L., Iwamoto Y., Theurl I., et al. Innate response activator B cells protect against microbial sepsis. Science 2012, 335:597-601.
41. Rhee J.S., Diaz R., Korets L., Hodgson J.G., Coussens L.M. TIMP-1 alters susceptibility to carcinogenesis. Cancer Res. 2004, 64:952-961.
42. Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., Barrette T., Pandey A., Chinnaiyan A.M. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6.
43. Ruffell B., Au A., Rugo H.S., Esserman L.J., Hwang E.S., Coussens L.M. Leukocyte composition of human breast cancer. Proc. Natl. Acad. Sci. USA 2012, 109:2796-2801.
44. Schioppa T., Moore R., Thompson R.G., Rosser E.C., Kulbe H., Nedospasov S., Mauri C., Coussens L.M., Balkwill F.R. B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc. Natl. Acad. Sci. USA 2011, 108:10662-10667.
45. Shah S., Divekar A.A., Hilchey S.P., Cho H.M., Newman C.L., Shin S.U., Nechustan H., Challita-Eid P.M., Segal B.M., Yi K.H., Rosenblatt J.D. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int. J. Cancer 2005, 117:574-586.
46. Silverman G.J. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms. Arthritis Rheum. 2006, 54:2356-2367.
47. Small E.J., Schellhammer P.F., Higano C.S., Redfern C.H., Nemunaitis J.J., Valone F.H., Verjee S.S., Jones L.A., Hershberg R.M. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J.Clin. Oncol. 2006, 24:3089-3094.
48. Tadmor T., Zhang Y., Cho H.M., Podack E.R., Rosenblatt J.D. The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model. Cancer Immunol. Immunother. 2011, 60:609-619.
49. Tan T.T., Coussens L.M. Humoral immunity, inflammation and cancer. Curr. Opin. Immunol. 2007, 19:209-216.
50. Tarella C., Passera R., Magni M., Benedetti F., Rossi A., Gueli A., Patti C., Parvis G., Ciceri F., Gallamini A., et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J.Clin. Oncol. 2011, 29:814-824.
51. van Kempen L.C.L., Rhee J.S., Dehne K., Lee J., Edwards D.R., Coussens L.M. Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. Differentiation 2002, 70:610-623.
52. Wansom D., Light E., Worden F., Prince M., Urba S., Chepeha D.B., Cordell K., Eisbruch A., Taylor J., D'Silva N., et al. Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch. Otolaryngol. Head Neck Surg. 2010, 136:1267-1273.
53. Wong S.C., Puaux A.L., Chittezhath M., Shalova I., Kajiji T.S., Wang X., Abastado J.P., Lam K.P., Biswas S.K. Macrophage polarization to a unique phenotype driven by B cells. Eur. J. Immunol. 2010, 40:2296-2307.